Is Myriad Genetics Inc (MYGN) overvalued? · rev $837.6M
Myriad Genetics Inc (MYGN) is a diagnostics & research company listed on NASDAQ.
This page asks whether Myriad Genetics Inc (MYGN) looks expensive on cached numbers — not a short thesis.
Latest reported MYGN revenue for 2024-12-31 was $837.6M. Net income was -$127.3M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. MYGN currently screens at market cap $413.7M.
MYGN currently screens at market cap $413.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MYGN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MYGN stock page for the full model, not this heading.
Not investment advice.